Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tommasina Guglielmelli

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Current Hematologic Malignancy Reports|October 1, 2013
Incorporating novel agents in the management of elderly myeloma patientsTommasina Guglielmelli, Antonio Palumbo
Expert Review of Hematology|January 14, 2015
Multiple myeloma: is a shift toward continuous therapy needed to move forward?Tommasina Guglielmelli, Antonio Palumbo
Expert Opinion on Biological Therapy|January 31, 2012
Update on the use of defibrotideTommasina Guglielmelli, Sara Bringhen, Antonio Palumbo
Journal of Oncology|December 17, 2009
Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemiaTommasina Guglielmelli, Roberta Merlini, Emilia Giugliano, et al.
Cancer Genetics and Cytogenetics|February 8, 2007
Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)Tommasina Guglielmelli, Emilia Giugliano, Susanna Cappia, et al.
Cancer Genetics and Cytogenetics|March 14, 2002
Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantationPatrizia Scaravaglio, Tommasina Guglielmelli, Emilia Giugliano, et al.
Oncoscience|June 23, 2015
mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR proteinTommasina Guglielmelli, Emilia Giugliano, Vanessa Brunetto, et al.
Cancer|May 1, 2007
Efficacy and safety of bortezomib in patients with plasma cell leukemiaPellegrino Musto, Fausto Rossini, Francesca Gay, et al.
Blood|August 6, 2010
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitorBao Hoang, Patrick Frost, Yijiang Shi, et al.
Cancer|August 7, 2008
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myelomaPellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Current Hematologic Malignancy Reports|October 1, 2013
Incorporating novel agents in the management of elderly myeloma patientsTommasina Guglielmelli, Antonio Palumbo
Expert Review of Hematology|January 14, 2015
Multiple myeloma: is a shift toward continuous therapy needed to move forward?Tommasina Guglielmelli, Antonio Palumbo
Expert Opinion on Biological Therapy|January 31, 2012
Update on the use of defibrotideTommasina Guglielmelli, Sara Bringhen, Antonio Palumbo
Journal of Oncology|December 17, 2009
Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemiaTommasina Guglielmelli, Roberta Merlini, Emilia Giugliano, et al.
Cancer Genetics and Cytogenetics|February 8, 2007
Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)Tommasina Guglielmelli, Emilia Giugliano, Susanna Cappia, et al.
Cancer Genetics and Cytogenetics|March 14, 2002
Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantationPatrizia Scaravaglio, Tommasina Guglielmelli, Emilia Giugliano, et al.
Oncoscience|June 23, 2015
mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR proteinTommasina Guglielmelli, Emilia Giugliano, Vanessa Brunetto, et al.
Cancer|May 1, 2007
Efficacy and safety of bortezomib in patients with plasma cell leukemiaPellegrino Musto, Fausto Rossini, Francesca Gay, et al.
Blood|August 6, 2010
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitorBao Hoang, Patrick Frost, Yijiang Shi, et al.
Cancer|August 7, 2008
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myelomaPellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, et al.
Pageof 3